Maze Therapeutics, Inc. Common Stock MAZE Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -38.7%— | —— | —— | —— | —— | |
| Return on assets | -32.6%— | -41.1%— | —— | —— | —— | |
| Return on invested capital | -117.8%— | —— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 17.9×+1.8× | 15.5×+5.7× | 17.7×— | 13.6×— | 16.1×— | |
| Quick ratio | 17.9×+1.8× | 15.5×+5.7× | 17.7×— | 13.6×— | 16.1×— | |
| Cash ratio | 9.4×-6.5× | 8.4×-1.1× | 14.3×— | 13.3×— | 15.8×— | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.1× | 0.1×— | 0.1×— | 0.1×— | 0.1×— | |
| Debt-to-assets | 0.1×+0.1× | 0.1×-0.1× | 0.1×— | 0.1×— | 0.1×— | |
| Per Share | ||||||
| Book value per share | $6.34-37.9% | $8.26+107% | $8.29— | $5.99— | $10.20— | |
| Valuation | ||||||
| Market capitalization | $1.48B+201% | $1.99B— | $1.14B— | $452.42M— | —— | |
| Enterprise value | $1.34B— | $1.83B— | $844.46M— | $212.89M— | —— | |
| Price / book | 4.3×— | 5.6×— | 3×— | 1.7×— | —— | |
| Free cash flow yield | -8.3%— | -5.7%— | —— | —— | —— | |
| Earnings yield | -8.3%— | -6.6%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Maze Therapeutics, Inc. Common Stock's ratios come from?
- Every ratio is computed from Maze Therapeutics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
